top of page

- Apr 29, 2016

Neurotech Announces Renewed Focus on NT-501 (CNTF) Encapsulated Cell Therapy Clinical Programs.

View PDF Version

4-29-16_neurotech_announces_renewedfocus

.

Download • 93KB

Recent Posts

Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hunter as Chief

Neurotech Pharmaceuticals Announces Positive Phase 3 Topline Results for NT-501 Implant in MacTel

Neurotech Chief Medical Officer authors article in The Ophthalmologist

bottom of page